Church & Dwight shares have risen 8.5% over the past 12 weeks, closely trailed by Amgen’s 8.2% gain.

Subcutaneous Tepezza demonstrated best-in-class efficacy with a 77% proptosis response, poised to replace IV infusions for over 25,000 patients and driving Tepezza revenue to $1.9 billion (+3% y/y). Full-year Q4 revenues rose 9% to $9.9 billion (10% volume growth), and quarterly sales are expected at $8.51 billion (+4.4% y/y) even as EPS may decline ~3% y/y. Obesity candidate MariTide shows strong weight-loss results and elevated commercial success probability, underpinning solid momentum in specialty and metabolic portfolios.

Government pricing reforms including TrumpRx mandate steep cuts and expanded coverage, while reimbursement policies, political scrutiny, and biosimilar competition pressure margins; manufacturing concentration in Puerto Rico and reliance on third parties create supply-chain constraints which can be exacerbated by public health threats; patent protection extending to 2040 underpins longer-term market exclusivity, and global clinical collaborations and regulatory approvals (such as conditional approval in China) are key for pipeline launches like tarlatamab and Tezepelumab in eosinophilic esophagitis.

Amgen is viewed as a value opportunity, with bullish analyst rankings, positive earnings ESP, discounted forward P/E metrics, and strong optimism around its clinical pipeline and broader biotech tailwinds, while Viridian shares face downside pressure amid heightened competition risk from Amgen’s Phase 3 success in thyroid eye disease.

Shares of Amgen plunged alongside most Dow blue-chips before rallying 10.6% since earnings, while ETF positioning shows a 3.85% weight in Amgen that underpins steady dividend flows.

Amgen’s revenues rose mid‐ to high‐single‐digit year‐over‐year, driven by robust sales of core and late‐stage pipeline medicines that more than offset biosimilar and mature product erosion. Management guides 2026 revenue of $37.0 billion–$38.4 billion with continued margin expansion on new high-margin launches, supported by strong free-cash-flow generation and capacity investments including site expansions and job additions.

Amgen’s Puerto Rico biomanufacturing hub is undergoing a $650 million capacity and workforce expansion. Multiple biosimilar launches for Prolia, Xgeva, Enbrel, and Stelara are set to accelerate legacy drug erosion globally. FDA regulators have flagged serious liver safety risks with Tavneos, mandating liver‐panel monitoring. Under the TrumpRx Most-Favored-Nation pricing regime, Amgen joined a six-company portal to sell 54 drugs at the lowest developed-nation rates directly to cash-pay patients, triggering Congressional scrutiny over transparency and actual savings. Patent litigation with Sanofi over cholesterol antibodies has been settled, resolving exclusivity disputes.

Analysts have mostly maintained Hold ratings but lifted price targets as enthusiasm builds around Amgen’s obesity and cardiometabolic pipeline, framing the shares as undervalued even after a strong run-up, while reproducibility doubts in cancer research and rocatinlimab trial halts have injected fresh caution. Patient discount programs for key therapies add a supportive narrative around access that tempers downside concern.

Substantial bullish put writing and pronounced post-earnings buying have driven AMGN shares through key technical levels, fueling a 10% one-month rally and 15% YTD gains.

Amgen delivered double-digit revenue and EPS growth in 2025 driven by broad-based volume gains across its blockbuster portfolio, generating robust free cash flow that funds dividends, buybacks and expanded capital expenditures to scale manufacturing capacity for upcoming pipeline launches, while guiding 2026 revenues of $37.0–$38.4 billion and non-GAAP EPS of $21.60–$23.00.

Biosimilar launches after patent expiries for Prolia, Xgeva and other legacy products, combined with intensifying drug pricing pressures under programs like 340B and heightened FDA scrutiny—including a Tavneos withdrawal request and related litigation—are set to erode sales and amplify regulatory risk moving into 2026.

Analysts and institutions show robust enthusiasm, with most ratings and price targets trending higher and narratives positioning Amgen as undervalued amid solid momentum and EPS upgrades. A minority of Hold-equivalent stances, warning flags on drug trials, and expected sales erosion introduce caution but have not dampened the prevailing optimistic narrative.

Amgen shares rallied 11.4% over 90 days, jumped 15.2% post-earnings to $341.75, then pulled back modestly into the low $327 range. Recent Dow gains were driven by other big caps, with Amgen closing around $327.3 in early January. Near-term price flows hinge on the upcoming February 3 earnings report.

Amgen delivered a 12.4% year-over-year revenue increase to $9.56 billion in the latest quarter, topping consensus forecasts near $9.46 billion. Analysts project a further ~4.2% sales rise next quarter but an ~11% EPS decline. Execution continues with the $840 million Dark Blue acquisition, Horizon integration, and late-stage MariTide GLP-1 trials bolstering a diversified pipeline.

Drug pricing reforms, biosimilar competition and upcoming patent expiries are pressuring market access and margins, while legal challenges over 340B discounts and high treatment costs in developing regions compound regulatory risk, even as pricing agreements, acquisitions, collaborations and regulatory filings aim to secure global commercialization and expand access.

Investors view Amgen as an undervalued, defensive dividend stock with upside tied to MariTide, driving multiple buy ratings and price-target lifts, though EPS forecasts and a Zacks Hold setting inject caution into near-term expectations.